Erasca’s License Agreement With Novartis

Latham & Watkins advised Erasca on the transaction.Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients…

This content is for Standard 1 Year members only.
Login Join Now
Laura Testa

Author: Laura Testa

This content is for Standard 1 Year members only.
Login Join Now